| Cardiovascular Risk Management |
1 |
1 |
| Cognitive Impairment |
0 |
0.9 |
| Lipids Management |
0 |
0.75 |
| Impairment |
0 |
0.62 |
| Type 2 Diabetes Mellitus |
0 |
0.95 |
| Mild Cognitive Impairment |
0 |
0.43 |
| Cognitive Deficits |
0 |
0.37 |
| Cardiometabolic Risk Factors |
0 |
0.35 |
| Hypertension |
0 |
0.35 |
| Heart Failure (HF) |
0 |
0.31 |
| Hyperlipidemia |
0 |
0.8 |
| Blood |
0 |
0.19 |
| Hyperglycemia |
0 |
0.6 |
| LDL Cholesterol |
0 |
0.19 |
| Statins |
0 |
0.19 |
| Hemoglobin A1c |
0 |
0.09 |
| Clinical Guidelines |
0 |
0.06 |
| Cognition |
0 |
0.06 |
| Comparative Effectiveness |
0 |
0.06 |
| Epidemiology |
0 |
0.06 |
| Health Care Quality, Access, and Evaluation |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Hemoglobin |
0 |
0.06 |
| New York |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Renal Failure |
0 |
0.06 |
| Sex Education |
0 |
0.06 |
| Social Determinants of Health |
0 |
0.06 |
| Sulfonylureas |
0 |
0.06 |